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We obtained sealed vials of two different polio vaccine lots, expiration date 1955, which were used in the first U.S. polio
vaccine campaign. These early lots were pulled from the market because they contained live infectious poliovirus which
caused polio in some of the vaccines. Theoretically, these vaccines could have contained other infectious retroviruses,
including HIV. No viral sequences were detected using RT-PCR analyses with primers capable of amplifying chimpanzee SIV
and HIV-1-related viruses nor with primers for macaque SIV, sooty mangabey SIV, and HIV-2-related viruses. Poliovirus
sequences were readily amplified by RT-PCR, suggesting that the technique used would have detected SIV or HIV sequences,
if present. © 2001 Academic Press(
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wIntroduction. The polio vaccine–HIV hypothesis stating
that polio vaccine lots in the 1950s may have been
contaminated with HIV or SIV, and thus caused the AIDS
epidemic, has recently gained major attention in both the
scientific and the lay press (7, 8). The lack of documented
vidence that only rhesus and green monkeys were used
or the preparation of the early polio vaccine lots, to-
ether with the apparent complete destruction of these
arly lots, which made testing for SIV and HIV impossi-
le, has fueled a controversy over the polio vaccine–HIV
ypothesis. No evidence of HIV or SIV gene sequences
as detected in 15 pools of oral polio vaccine produced
etween 1975 and 1984 (6). Until recently, no vaccines
roduced prior to 1975 have been available for analysis.
dward Hooper, a proponent of the oral polio vaccine–
IV hypothesis, called for the remaining samples of
HAT 13, a vaccine lot he suspected of causing the AIDS
pidemic, to be analyzed for the presence of HIV/SIV (3,
). The results of this multilaboratory “blinded” study
ere presented at a 2-day conference sponsored by
ritain’s Royal Society (2). All laboratories that tested the
accine samples could not detect the presence of HIV/
IV. All HIV-1 strains are closely related phylogenetically
o SIVcpz (chimpanzee) strains infecting Pan troglodytes
roglodytes, indicating that this subtype of chimpanzee
as the source of the AIDS epidemic (5). Questions
oncerning the exact species of monkeys used in the
roduction of early polio vaccines have recently arisen
1 Deceased.
2 sTo whom reprint requests should be addressed.
137), but the analysis of the CHAT 13 lot indicates that the
accines had been grown in macaque kidney cells (2).
Injectable polio vaccines could have represented a
uch more dangerous source for HIV infection than
ral polio vaccines, if contaminated with live HIV. How-
ver, injectable polio vaccines were inactivated with
ormaldehyde, which killed the poliovirus and presum-
bly any other contaminating retrovirus. Thus, inject-
ble polio vaccines are unlikely contributors to the
pread of the AIDS epidemic, except for the very early
olio vaccine lots. The inactivating process was inef-
icient in the early injectable polio vaccine lots and
ive, infectious poliovirus, and presumably any possi-
le contaminating retrovirus, was present in some of
hose lots, which resulted in a few polio epidemics.
or these reasons, some of these lots had to be pulled
rom the market. We acquired sealed injectable polio
accine vials from two such lots (028846B and
28863B; Parke Davis) prepared some time in 1954 (9).
etters from the FDA and polio vaccine manufacturers
tated that they had no additional vials from before
963, thus it appears that our vials are the last existing
ials of the very early polio vaccine. The two lots we
btained were used in the first polio vaccine campaign
n the United States. They were prepared in “monkey
idney cells,” but the type of monkey was not speci-
ied. This is not unexpected, since there were no major
oncerns at that time associated with the use of mon-
ey cells, which were often shipped to laboratories
ithout further labeling. In these lots, we demon-trated the presence of archetypal SV40 (9). In the
0042-6822/01 $35.00
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14 RAPID COMMUNICATIONpresent study, using RT-PCR analysis, we analyzed
both lots of the vaccine for HIV and related viruses.
Results. Both lots were tested for the presence of HIV
nd SIV. Three different RNA extraction procedures were
sed to verify the accuracy and reproducibility of the
esults. No viral sequences were detected using two
ifferent sets of primers specific for HIV-1 group M (Fig.
a). We next used the HPOL set of primers, which am-
lifies HIV-1 sequences of very diverse geographical and
enetic origin. This set of primers amplifies HIV group M,
roup N, and group O and SIVcpzGAB-1, SIVcpzGAB-2,
nd SIVcpzANT. Polio vaccines tested repeatedly nega-
ive for HIV or SIV sequences (Fig. 1b). Furthermore, we
ested two additional sets of primers specific for two
ifferent strains of SIVcpz. Polio vaccines tested negative
ith SIVcpzANT-specific primers, whereas controls were
asily amplified (Fig. 1c). Primers specific for SIVcpzUS
ere designed by us (HPOL-US.for, 59 CCA TAC AAT
CCA CAA AGT CAA AGT CAA GG; HPOL-US.rev, 59 TAC
GC CCC TTC ACC TTT CCA; HPOL-US.for.nested, 59
AA GAC AGC TGT ACA GAT GGC AG; HPOL-
S.rev.nested, 59 CTC TGC TGT CCC TGT AAT A). Polio
accines tested negative with SIVcpzUS-specific prim-
rs. We could not obtain any SIVcpzUS positive control;
owever, these primers also amplified the closely related
IV-1 and SIVcpzANT, which were included as controls
n these experiments (Fig. 1d). An ELISA for the detection
f p24, the HIV core protein, in the polio vaccines was
lso negative.
Subsequently we analyzed the vaccines for the sec-
nd group of immunodeficiency viruses, which includes
everal types of SIV and HIV-2. Rhesus monkey kidney
ells were commonly used to prepare polio vaccines. It
s unknown if the rhesus monkeys used in 1954–1955
ere infected with SIVmac, which occurred when rhesus
onkeys were housed together with macaques. We de-
igned primers (SIVgag) for a nested PCR in the gag
egion of SIVmac. No sequences were detected in the
olio vaccine (Fig. 1e). We repeated the screening for
IVmac using a new set of primers (SIV59gag/SIV39gag)
hat amplifies a different sequence in the gag gene,
hich is conserved among different strains of SIV, in-
luding SIVmac, SIVsm (sooty mangabey), and all HIV-2-
elated SIV isolates. No SIV or HIV-2-related sequences
ere detected in the polio vaccine RNA (Fig. 1f). No viral
equences were detected using RT-PCR analyses with
rimers capable of amplifying SIV chimpanzee and HIV-
-related viruses nor with primers for macaque SIV, sooty
angabey SIV, and HIV-2-related viruses. In every exper-
ment we were able to amplify poliovirus RNA, which
uggests that the technical procedure was adequate.
Discussion. If AIDS had been spread through contam-
nated polio vaccines, it could have been spread through
he oral (Sabin and Koprowski) or the injectable (Salk)
olio vaccine. The injectable polio vaccines would have
een a far more dangerous source of infection if liveFIG. 1. (a) Ethidium bromide staining of the seminested PCR products
obtained with P56/P63 primers, which amplify a fragment of the HIV-1 pol
region, and with PE2/P31 primers, which amplify a fragment of the gp
120–gp 41 junction region. The arrow points to the target sequence
amplified in the controls. Lane 1, polio vaccine; lane 2, serum of HIV-1-
positive patient, positive control; lane 3, water, negative control; lane 4,
human DNA, negative control; lane 5, HIV-1 DNA, positive control; S, DNA
ladder. (b) Ethidium bromide staining of the nested PCR products obtained
with the primer set HPOL, specific for HIV-1 pol. The arrows point to the
target sequence amplified in the controls. Lane 1, polio vaccine; lane 2,
serum of HIV-1-positive patient, positive control; lane 3, water, negative
control; lane 4, human DNA, negative control; lane 5, water, negative
control; lane 6, HIV-1 DNA, positive control; S, DNA ladder. (c) Ethidium
bromide staining of the nested PCR products obtained with the primers
specific for SIVcpzANT. The arrow points to the target sequence amplified
in the controls. Lane 1, polio vaccine; lane 2, polio vaccine; lane 3, polio
vaccine; lane 4, SIV cpzANT DNA (500 ng). Samples 1–3 represent three
different RNA extractions (see Appendix). (d) Ethidium bromide staining of
the nested PCR products obtained with the primer set HPOL, specific for
SIVcpzUS. The arrow points to the target sequence amplified in the
controls. Lane 1, polio vaccine; lane 2, HIV-1-positive human serum; lane 3,
SIV cpzANT DNA (500 ng); lane 4, SIVcpzANT DNA (50 ng); lane 5, PCR
negative control. (e) Ethidium bromide staining of the nested PCR products
obtained using the SIVgag set of primers. The arrow points to the target
sequence amplified in the controls. Lane 1, polio vaccine; lane 2,
SIV-negative monkey serum; lane 3, water, negative control; lane 4,
SIV-negative monkey DNA from peripheral white blood cells; lane 5,
SIV-positive monkey DNA from peripheral white blood cells; lane 6,
SIV-positive monkey serum. S, DNA ladder. (f) Ethidium bromide staining of
the seminested PCR products obtained with the SIV59gag/SIV39 gag
primers. The arrow points to the target sequence amplified in the controls.
Lane 1, polio vaccine; lane 2, SIV-negative monkey serum; lane 3, SIV-
positive monkey serum (no RT); lane 4, water, negative control; lane 5,
SIV-positive monkey DNA from peripheral blood cells; lane 6, SIV-positive
monkey serum; S, DNA ladder.
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15RAPID COMMUNICATIONvirus was present. Although these vaccines were inacti-
vated with formalin, the inactivation process was initially
not very efficient. Infectious poliovirus (which is also an
RNA virus) was sometimes present, resulting in the de-
velopment of occasional polio epidemics. For this rea-
son, some of the early batches of polio vaccines were
pulled from the market and replaced with safer vaccines
(7). HIV and SIV could potentially have spread through
this route if present in these early lots of polio vaccines.
Because there are no records regarding the types of
monkeys used in the preparation of the first lots of
injectable polio vaccines, there was some reason for
concern. In the years after 1955, the inactivation process
was improved and the types of monkeys used were
recorded, making it unlikely that later inactivated polio
vaccines contained infectious HIV or related viruses. We
found no evidence of SIV- or HIV-related sequences in
two separate lots of polio vaccine used in the first U.S.
campaign against polio. In addition, samples of lot CHAT
13 prepared by Dr. Koprowski have also tested negative
through the multilaboratory study for HIV and related
viruses, presented at the Royal Society Conference (2, 3).
Together, these findings with our data make it reason-
able to state that it is extremely unlikely that polio vac-
cines caused the AIDS epidemic.
Materials and Methods. Two unopened 9-ml vials of
olio vaccine manufactured by Parke Davis were ana-
yzed in this study: the first was from Lot 028863B—
xpiration date October 15, 1955; the second was from
ot 028846B—expiration date October 12, 1955. These
ials were kindly provided by Dr. Herbert Ratner, who
eceived them from the National Foundation of Infantile
aralysis when he served as the Director of Public
ealth in Oak Park, Illinois. Dr. Ratner stored these vials
or future analysis until 1997, when he gave them to our
ab for testing. SIV-positive and SIV-negative rhesus
onkey sera and DNA from peripheral blood cells of
IV-positive and SIV-negative rhesus monkeys were
indly provided by Ann Rosenthal at the California Re-
ional Primate Research Center, University of California
t Davis. HIV-1-positive and HIV-1-negative human sera
ere obtained from the Department of Pathology at Loy-
la. Sooty mangabey SIV-positive and SIV-negative se-
um was kindly provided by Dr. H. McClure at the Yerkes
egional Primate Research Center, Emory University, At-
anta, Georgia. SIVcpzANT DNA and PCR primers spe-
ific for SIV cpzANT DNA were provided by Dr. Heeney at
he Biomedical Research Primate Center, Rijswijk, The
etherlands.
RNA extraction. Extraction from the human and mon-
ey sera was performed using the Qiagen viral RNA kit
Valencia, CA). To reduce the possibility of false negative
esults, three different technical approaches were used
o extract RNA from Lot 028846B, of which several vials
ere available. Only one approach was used, however,
or Lot 028863B because only one vial was available. HFirst approach: To pellet eventual RNA viruses present in
the polio vaccine, we spun 2 ml of polio vaccine (1 ml of
polio vaccine Lot 028863B and 1 ml of Lot 028846B,
combined) overnight at 30,000 rpm on a TLA100.2 rotor in
a Beckman ultracentrifuge, resuspended the pellet in 140
ml of PBS, and extracted the RNA using the Qiagen viral
RNA kit according to the protocol of T. Zhu et al. (10).
econd approach: 1 ml of vaccine (Lot 028846B) was
ncubated with 4 ml of lysis buffer from the Qiagen viral
NA kit. The RNA was then precipitated and resus-
ended in 50 ml of RNase-free water. Third approach:
he RNA-STAT-50 solution (Tel-Test, Friendswood, TX)
as used to extract RNA from 500 ml of polio vaccine Lot
028846B, according to the manufacturer’s protocol. The
RNA pellet was resuspended in 100 ml of RNase-free
water. All three approaches gave RNA suitable for RT-
PCR amplification, as demonstrated by the successful
amplification of poliovirus sequences (see below). The
second and third approach gave a higher yield of RNA.
RT-PCR for HIV-1 and Poliovirus. Twenty-two microli-
ters of RNA was incubated with one of the following: an
oligonucleotide (POL1, see below) specific for the polio-
virus to verify that the RNA was suitable for RT-PCR
analysis or a mixture of both an oligonucleotide (P58)
specific for the HIV-1 pol gene and an oligonucleotide
(PE2) specific for the gp120–gp41 junction (10) or with the
HPOL 4538 oligonucleotide (4). The primer concentration
was 1.6 ng/ml in a final volume of 24 ml. The mixture was
heated at 70°C for 10 min and then equilibrated at room
temperature. The RNA was reverse transcribed using a
Promega kit. Briefly, total RNA was incubated for 1 h at
42°C in a reaction containing 0.3 mM dNTP, 2.5 mM
MgCl2, reverse transcriptase buffer 13, 0.87 ml of RNase
nhibitor, and 40 units of AMV reverse transcriptase. The
nzyme was then inactivated by incubation at 70°C for 15
in. Ten microliters of the reaction was analyzed in by
CR using AmpliTaq polymerase (Perkin–Elmer). The fol-
owing primers were used at the final concentration of
.5 mM: POL1/POL2 (control, human poliovirus, strain
abin 1 POL2 nt 203–226 and POL1 nt 61–83), P63/P58,
nd PE11/PE2 (10) and HPOL 4538/HPOL 4235 (4). Cy-
ling conditions for all of the primers were 3 min at 95°C
1 cycle), 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C
or 45 cycles followed by a 10-min extension, except for
he HPOL set of primers, for which the annealing tem-
erature was lowered to 50°C. Ten microliters of the PCR
roduct obtained with the HIV-1-specific primers was
eamplified for 45 cycles in a seminested PCR using
rimers P56/P63, for the product obtained with P63/P58,
nd P31/PE2 for the product obtained with PE11/PE2. In
nested PCR, the primers HPOL 4327/HPOL 4481 were
sed to reamplify the products obtained with HPOL 4538/
POL 4235.
Sensitivity of HIV-1 Primers. To test the sensitivity of
he primers HPOL 4538/HPOL 4235 (outer primers) andPOL 4327/HPOL 4481 (inner primers) and primers P58/
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16 RAPID COMMUNICATIONP63 and p56/p63 we used sera of two HIV-positive pa-
tients. The titers of these two sera were measured using
a commercially available kit (Amplicor HIV1 Monitor test
from Roche Diagnostic, Indianapolis, IN). HIV-1-positive
sera were serially diluted down to 1 copy/140 ml of polio
vaccine and the RNA was extracted using a Qiagen kit
and tested by RT-PCR, as described above. In these
experiments the limit of detection was between 50 (for
the HIV-1-positive serum 1) and 148 (for the HIV-1-posi-
tive serum 2) copies of HIV-1 in the initial 140 ml of the
olio vaccine mixture (Fig. 2).
RT-PCR for SIV. Fifteen microliters of RNA was incu-
ated with either an oligonucleotide specific for the po-
iovirus (POL1) or an oligonucleotide specific for the
IVmac gag gene (SIVgag.rev.outer, 59 CAC CAG ATG
ACG CAG ACA GT). cDNA synthesis was performed as
described above for HIV-1. Ten microliters of the reaction
was analyzed in a 100-ml PCR using AmpliTaq polymer-
ase (Perkin–Elmer). The following primers were used at
a final concentration of 0.5 mM: POL1 and POL2 (human
poliovirus, strain Sabin 1) and SIVgag.rev.outer and SIV-
gag.for.outer (59 CGG CGG AAA GAA AAA GTA CA).
Cycling conditions were 3 min at 95°C (1 cycle), 1 min at
95°C, 1 min at 55°C, and 1 min at 72°C for 45 cycles
followed by a 10-min extension. Ten microliters of the
PCR products obtained with the SIV-specific primers was
reamplified for 45 cycles in a nested PCR (SIVgag.for.in-
ner, 59 GCA TGT AGT ATG GGC AGC AA, and SIVgag.
rev.inner, 59 TTC TGA GCC TGT TGG CAC TA). The same
FIG. 2. Sensitivity of HIV-1 primers. (a) Ethidium bromide staining of
the seminested PCR products obtained with the primers P63/P56 spe-
cific for HIV-1 pol. The arrow points to the target sequence amplified in
the positive controls. Lane 1, undiluted HIV-1-positive serum (16,380
copies); lane 2, HIV-1-positive serum diluted in polio vaccine (1638
copies); lane 3, HIV-1-positive serum diluted in polio vaccine (148
copies); lane 4, HIV-1-positive serum diluted in polio vaccine (13 cop-
ies); lane 5, HIV-1-positive serum diluted in poliovaccine (1 copy); lane
6, polio vaccine; lane 7, HIV-positive serum (no RT); lane 8, PCR-positive
control; lane 9, water negative control. (b) Ethidium bromide staining of
the nested PCR products obtained with the primers HPOL specific for
HIV-1 pol. The arrow points to the target sequence amplified in the
positive controls. Lane 1, undiluted HIV-1-positive serum (16,380 cop-
ies); lane 2, HIV-1-positive serum diluted in polio vaccine (1638 copies);
lane 3, HIV-1-positive serum diluted in polio vaccine (148 copies); lane
4, HIV-1-positive serum diluted in polio vaccine (13 copies); lane 5,
HIV-1-positive serum diluted in polio vaccine (1 copy); lane 6, polio
vaccine; lane 7, HIV-positive serum (no RT); lane 8, PCR-positive control;
lane 9, PCR-negative control.experiment was then repeated using a different set ofprimers (SIV59gag/SIV39gag) which also targets the gag
gene of all HIV-2-related SIV strains and amplifies “all the
HIV-2 related SIV isolates” as described by S. I. Staprans
et al. in “Quantitative methods to monitor viral load in
simian immunodeficiency virus infections” (1). Ten micro-
liters of PCR product obtained with the SIV-specific prim-
ers was reamplified for 45 cycles in a seminested PCR
using primers SIV59gag/SIVgag.rev.outer for the product
obtained with SIV59gag/SIV39gag. In the experiments de-
scribed above we used SIVmac-positive sera. Concern-
ing other SIV strains, these should have been detected if
present, at least by the primers designed by Staprans et
al. (see above). However, inspection of the sequences of
these primers with the Los Alamos sequences database
revealed that the alignment contained some mismatches
with SIVsm. We therefore tested the ability and sensitivity
of the primers SIV59gag/SIV39gag to amplify SIVsm.
Testing the Sensitivity of the SIV59gag/SIV39gag and
Seminested Primers for SIVsm Sequence Amplification.
Sooty Mangabey SIV (SIVsm) RNA was amplified using
the set of primers SIV59gag/SIV39gag and seminested
SIV59gag-SIVgag.rev.outer (see above). To test the sen-
sitivity of these primers, SIVsm-positive serum was seri-
ally diluted in polio vaccine; the RNA was extracted and
analyzed by RT-PCR. This serum was kindly provided by
Dr. McClure, Yerkes Regional Primate Center (Atlanta,
GA) and the SIVsm titer was unknown. However, we
were able to detect SIVsm sequences in serum diluted
up to 1 to 104 in polio vaccine (Fig. 3). These experiments
onfirmed that the primers we used amplify SIVsm se-
uences.
FIG. 3. SIVsm serum diluted in polio vaccine. Ethidium bromide
staining of the seminested PCR products obtained using the primers
SIV59gag/SIVgag.rev.outer. The arrow points to the target sequence
amplified in the positive controls. Lane 1, undiluted SIV-positive Sooty
Mangabey serum; lane 2, SIV-positive Sooty Mangabey serum diluted
in polio vaccine (1 to 10); lane 3, SIV-positive Sooty Mangabey serum
diluted in polio vaccine (1 to 102); lane 4, SIV-positive Sooty Mangabey
serum diluted in polio vaccine (1 to 103); lane 5, SIV-positive Sooty
Mangabey serum diluted in polio vaccine (1 to 104); lane 6, polio
accine; lane 7, SIV-positive serum (no RT); lane 8, PCR-positive control;
ane 9, PCR-negative control.
FIG. 4. Ethidium bromide staining of the nested PCR products ob-
tained with the HPOL primers. The arrow points to the target sequence
amplified in the controls. Lane 1, 500 ng SIVcpzANT DNA; lane 2, 250
ng SIVcpzANT DNA; lane 3, 125 ng SIVcpzANT DNA; lane 4, 61 ng
SIVcpzANT; lane 5, 5 ng SIVcpzANT DNA; lane 6, PCR-negative control;
lane 7, PCR-positive control.
17RAPID COMMUNICATIONTest to Verify the Ability of the HPOL Primers to Amplify
SIVcpzANT. DNA from SIVcpz ANT was serially diluted in
water and tested by PCR using the HPOL set of primers.
These experiments revealed that the limit of detection
was 61 ng (Fig. 4). Polio vaccines tested negative for
these primers (see Fig. 1).
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